Inspire Medical Systems Q3 Earnings Call Highlights
Inspire Medical Systems (INSP) reported Q3 earnings, estimating coding and reimbursement challenges reduced results by $30M and may impact 2026 results by $120M. The company expects revenue growth in Q4 and low-single-digit growth in 2027, citing stable coding and investments. Inspire highlighted a new CPT code for its Inspire V device and ongoing development of Inspire VI. Management discussed clinical evidence supporting their therapy and plans to invest in patient access and education.
How this was made
The 30-second read
Why it matters
The earnings call revealed a $30M hit to Q3 results and a $120M full‑year impact due to coding and reimbursement issues, while also announcing a Category I CPT code effective 2028 that may streamline billing.
Market read
The disclosed financial impact and regulatory progress are material for investors, influencing short‑term price and long‑term growth outlook.
What to watch
Potential cardiology referral expansion and battery‑replacement revenue could boost margins beyond current guidance.
Background
Inspire Medical Systems (NYSE:INSP) provides implantable hypoglossal nerve stimulation devices for obstructive sleep apnea.
Ticker impact
Q3 earnings call disclosed $30M coding/reimbursement hit and $120M full‑year impact, plus approval of a Category I CPT code effective 2028.
likely downside as market prices in the $30M hit, with potential recovery once the CPT code simplifies reimbursement.
Guidance reduction is a concrete, newly disclosed figure that directly affects earnings expectations; the CPT approval is a positive catalyst but its benefit is farther out.
Market effects
Sleep‑apnea device sector may see broader scrutiny of coding practices, but the new CPT code could set a precedent for other manufacturers.
U.S. healthcare reimbursement environment; limited impact on international markets beyond Germany destocking note.
Modest; primarily affects Inspire and peers in the medical‑device space.
Counterpoint
Investors could view the CPT code approval as a longer‑term growth catalyst that outweighs the near‑term coding hit.
Key entities
- companyInspire Medical Systems
Developer of the Inspire V hypoglossal nerve stimulation system.
- regulatorCMS
Centers for Medicare & Medicaid Services, pending final payment rule.
